In this edition:
KEYNOTE-671: perioperative pembrolizumab in resectable, earlystage NSCLC
CheckMate 77T: neoadjuvant nivolumab + chemotherapy, followed by surgery & adjuvant nivolumab in resectable NSCLC
ALINA: adjuvant alectinib in ALK+ NSCLC
ATTLAS: atezolizumab + bevacizumab & chemotherapy EGFR/ALK-mutated NSCLC
MARIPOSA: amivantamab + lazertinib in EGFR-mutated NSCLC
FLAURA2: osimertinib + chemotherapy EGFR-mutated NSCLC
PAPILLON: amivantamab + chemotherapy EGFR exon 20 insertion-mutated NSCLC
MARIPOSA-2: amivantamab + chemotherapy ± lazertinib in EGFRmutated NSCLC after progression on osimertinib
TROPION-Lung01: Dato-DXd vs. docetaxel in advanced/metastatic NSCLC
SAPPHIRE: sitravatinib + nivolumab vs. docetaxel in advanced nonsquamous NSCLC
Please login below to download this issue (PDF)